Given the complexity of tumor immune evasion mechanisms, rational combination approaches will be essential, including immunotherapy–chemotherapy combinations, immunotherapy-targeted therapy regimens, and combinations of distinct immunotherapies, exemplified by the promising strategy of combining IDH1 neoantigen vaccines with PD-1/PD-L1 checkpoint inhibitors to overcome TME-mediated immunosuppression [105]. Here, IDH1 is linked to neoplasm.